Hyperthermic Intraperitoneal Chemotherapy

Phase 2Small molecule

Hyperthermic Intraperitoneal Chemotherapy is one of 149 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

148

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Esophageal CancerActive, not recruiting

MesotheliomaActive, not recruiting

Pancreatic CancerActive, not recruiting

Gastric CancerActive, not recruiting

Peritoneal Malignant MesotheliomaRecruiting

Clinical Stage I Gastric Cancer AJCC V8Enrolling by invitation

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

Esophageal CancerPhase 2

Active, not recruiting

MesotheliomaPhase 2

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

Peritoneal Malignant MesotheliomaPhase 2

Recruiting

Clinical Stage I Gastric Cancer AJCC V8Phase 2

Enrolling by invitation

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Hyperthermic Intraperitoneal Chemotherapy

MMayo Clinic

Phase 2

1 2

Gemzar

GGynecologic Oncology Group

Byetta

1 4

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 5

ABI-007

Bristol-Myers Squibb

Preclinical

2 6

Chemotherapy Agents

Takeda

Preclinical

1 7

LDE225

Novartis

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Thiazolidinediones

Sanofi

Preclinical

1 10

Secretin-Ferring

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Peritoneal Malignant Mesothelioma

NCT05001880

Q4 2026

Phase 1Recruiting

Intraperitoneal Chemotherapy

NCT05415709

Phase 2Not yet recruiting

Intraperitoneal Chemotherapy

NCT06544460

Q4 2027

Phase 3Active, not recruiting

Gastric Cancer

NCT03348150

Q1 2028

Phase 2Recruiting

Gastric Cancer

NCT05753306

Clinical

Trials by Indication[1]

Gastric Cancer4 trials

Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer With Peritoneal Metastatis

Unknown status·GGuangdong Provincial Hospital of Traditional Chinese Medicine·Phase 2·NCT03604614·56 enrolled

Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer

Completed·LLoma Linda University·Phase 1·NCT02672865·4 enrolled

Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.

Active, not recruiting·TThe Netherlands Cancer Institute·Phase 3·NCT03348150·102 enrolled

Show 1 more trial

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

Recruiting·MMayo Clinic·Phase 2·NCT05753306·40 enrolled

Intraperitoneal Chemotherapy2 trials

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Recruiting·OOhio State University Comprehensive Cancer Center·Phase 1·NCT05415709·45 enrolled

Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients

Not yet recruiting·FFudan University·Phase 2·NCT06544460·94 enrolled

Pediatric Patients1 trial

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients

Terminated·MMayo Clinic·Phase 1·NCT04213794·2 enrolled

Pancreatic Cancer1 trial

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis

Recruiting·MMayo Clinic·Phase 2·NCT04858009·40 enrolled

Esophageal Cancer1 trial

Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02891447·24 enrolled

3 more indications

Oxaliplatin1 trial

Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix

Completed·WWake Forest University Health Sciences·Phase 2·NCT01580410·136 enrolled

Peritoneal Malignant Mesothelioma1 trial

Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05001880·66 enrolled

Clinical Stage I Gastric Cancer AJCC v81 trial

Prophylactic Hyperthermic IntraperitOneal Chemotherapy (p-HIPEC) for pRevention of perItONeal Recurrence in Gastric Cancer: MC240402 (HORIZON) Trial

Enrolling by invitation·MMayo Clinic·Phase 2·NCT07139951·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Hyperthermic Intraperitoneal Chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hyperthermic Intraperitoneal Chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hyperthermic Intraperitoneal Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMayo Clinic

Hyperthermic Intraperitoneal Chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q4 2027

Q1 2028

Trials by Indication[1]

Gastric Cancer4 trials

Intraperitoneal Chemotherapy2 trials

Pediatric Patients1 trial

Pancreatic Cancer1 trial

Esophageal Cancer1 trial

Oxaliplatin1 trial

Peritoneal Malignant Mesothelioma1 trial

Clinical Stage I Gastric Cancer AJCC v81 trial

References

Drug Info

Quick Facts

Related News